Cantor’s William Tanner anticipates TXMD will turn to financing before the company’s VVA asset TX-04 faces its new PDUFA date with destiny: May 29, 2018.
Cantor’s William Tanner smirks as bears run low on “ammunition” to doubt TXMD on the heels of news of an NDA resubmission to the FDA for TX-004.
In a multi-billion dollar industry fighting for alpha, Laurion Capital’s Benjamin Smith is betting on these two healthcare stocks for success. But while …
Billion-dollar Laurion fund initiates new positions in TEVA and TXMD.
Oppenheimer predicts TXMD to launch TX-004HR by mid-2018 with a January approval from the FDA.
As TherapeuticsMD Inc (NASDAQ:TXMD) shares take off to the rocket fuel tune of 35%, Cantor analyst William Tanner bullishly backs soaring investor sentiment. Story Continues
These two pharma stocks all have upside of over 100% say top Wall Street analysts.
